{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:28Z","timestamp":1792166308243,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018148","name":"Heron Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["63\/313,823"],"award-info":[{"award-number":["63\/313,823"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","award":["AGR-11611SOW1"],"award-info":[{"award-number":["AGR-11611SOW1"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012728","name":"Frederick National Laboratory for Cancer Research","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007899","name":"University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015015","name":"Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NKp30"],"award-info":[{"award-number":["NKp30"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2021\\u2013ID26037"],"award-info":[{"award-number":["IG2021\\u2013ID26037"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014042","name":"Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH1910269"],"award-info":[{"award-number":["W81XWH1910269"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["T32CA078207"],"award-info":[{"award-number":["T32CA078207"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","award":["2019.866"],"award-info":[{"award-number":["2019.866"]}],"id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ccell.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T10:58:19Z","timestamp":1662980299000},"page":"1027-1043.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"B\u00e9reng\u00e8re","family":"Salom\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Daza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Charap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Banchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Fu","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeh","family":"Izadmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Geanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo M.","family":"de Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin G.","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshuo A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-chih","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin Htwe","family":"Thin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Garcia-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardo","family":"Hegewisch-Solloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Chowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Fernandez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Skobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Sebra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Clancy-Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice O.","family":"Kamphorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Johan","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Marcenaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Carrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Mellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Mariathasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2022.08.005_bib1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.08.005_bib2","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.4049\/jimmunol.144.8.3238","article-title":"A novel functional cell surface dimer (Kp43) expressed by natural killer cells and I cell receptor-gamma\/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody","volume":"144","author":"Aramburu","year":"1990","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib3","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib4","doi-asserted-by":"crossref","first-page":"e002231","DOI":"10.1136\/jitc-2020-002231","article-title":"Intratumoral CD103+ CD8+ T\u00a0cells predict response to PD-L1 blockade","volume":"9","author":"Banchereau","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ccell.2022.08.005_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T\u00a0cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.08.005_bib67","doi-asserted-by":"crossref","first-page":"28232","DOI":"10.1073\/pnas.2013554117","article-title":"HLA tapasin independence: broader peptide repertoire and HIV control","volume":"117","author":"Bashirova","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccell.2022.08.005_bib6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","article-title":"Generalizing RNA velocity to transient cell states through dynamical modeling","volume":"38","author":"Bergen","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2022.08.005_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y","article-title":"Transforming growth factor- I -induced expression of CD94\/NKG2A inhibitory receptors in human T lymphocytes","volume":"29","author":"Bertone","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ijc.33859","article-title":"NKG2A is a late immune checkpoint on CD8 T\u00a0cells and marks repeated stimulation and cell division","volume":"150","author":"Borst","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ccell.2022.08.005_bib9","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1074-7613(00)80008-4","article-title":"Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell\u2013associated CD94\/NKG2 receptors","volume":"10","author":"Boyington","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.08.005_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1084\/jem.185.4.795","article-title":"NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor","volume":"185","author":"Brooks","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/eji.1830270230","article-title":"The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules","volume":"27","author":"Carretero","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2022.08.005_bib14","doi-asserted-by":"crossref","first-page":"e99432","DOI":"10.1371\/journal.pone.0099432","article-title":"Prostaglandin E2 promotes features of replicative senescence in chronically activated human CD8+ T\u00a0cells","volume":"9","author":"Chou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2022.08.005_bib15","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1172\/JCI128480","article-title":"Setting traps for NKG2A gives NK cell immunotherapy a fighting chance","volume":"129","author":"Cichocki","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2022.08.005_bib16","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.08.005_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12859-021-04054-2","article-title":"CytoTree: an R\/Bioconductor package for analysis and visualization of flow and mass cytometry data","volume":"22","author":"Dai","year":"2021","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ccell.2022.08.005_bib18","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T\u00a0cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.08.005_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor Immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ccell.2022.08.005_bib20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.celrep.2018.12.014","article-title":"Microtubule-driven stress granule dynamics regulate inhibitory immune checkpoint expression in T\u00a0cells","volume":"26","author":"Franchini","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2022.08.005_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/0008-5472.CAN-12-2569","article-title":"CD103 or LFA-1 engagement at the immune synapse between cytotoxic T\u00a0cells and tumor cells promotes maturation and regulates T-cell effector functions","volume":"73","author":"Franciszkiewicz","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2022.08.005_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.celrep.2016.05.095","article-title":"NKp80 defines a critical step during human natural killer cell development","volume":"16","author":"Freud","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2022.08.005_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2022.08.005_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of immune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.08.005_bib27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/eji.200425735","article-title":"The role of TCR stimulation and TGF-beta in controlling the expression of CD94\/NKG2A receptors on CD8 T\u00a0cells","volume":"35","author":"Gunturi","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2020.11.035","article-title":"TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T\u00a0cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer","volume":"499","author":"Han","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ccell.2022.08.005_bib66","doi-asserted-by":"crossref","first-page":"10770","DOI":"10.1038\/s41598-018-28791-2","article-title":"A Universal Live Cell Barcoding-Platform for Multiplexed Human Single Cell Analysis","volume":"8","author":"Hartmann","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ccell.2022.08.005_bib29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T\u00a0cell exhaustion inChronic infection and cancer: opportunities for interventions","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","author":"Herbst","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2022.08.005_bib31","doi-asserted-by":"crossref","first-page":"eaag1672","DOI":"10.1126\/sciimmunol.aag1672","article-title":"Class I HLA haplotypes form two schools that educate NK cells in different ways","volume":"1","author":"Horowitz","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib32","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T\u00a0cells with an effector-like transcriptional signature emerge from PD-1(+) stem-like CD8(+) T\u00a0cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.08.005_bib33","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.08.005_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T\u00a0cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.08.005_bib35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T\u00a0cells by PD-1\u2013targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.08.005_bib36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/1097-0142(20010915)92:6<1475::AID-CNCR1472>3.0.CO;2-X","article-title":"Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder","volume":"92","author":"Kim","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2022.08.005_bib37","first-page":"183","article-title":"Optimizing high-performance computing systems for biomedical workloads","volume":"2020","author":"Kovatch","year":"2020","journal-title":"IEEE Int. Symp. Parallel Distrib. Process. Workshops Phd Forum"},{"key":"10.1016\/j.ccell.2022.08.005_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41586-018-0414-6","article-title":"RNA velocity of single cells","volume":"560","author":"La Manno","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.08.005_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41592-021-01346-6","article-title":"CellRank for directed single-cell fate mapping","volume":"19","author":"Lange","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2022.08.005_bib40","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.08.005_bib41","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2022.08.005_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T\u00a0cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.08.005_bib43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T\u00a0cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib44","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/cas.14888","article-title":"Tertiary lymphoid structures show infiltration of effective tumor-resident T\u00a0cells in gastric cancer","volume":"112","author":"Mori","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ccell.2022.08.005_bib45","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ccell.2022.08.005_bib46","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.4049\/jimmunol.2000434","article-title":"Notch regulates innate lymphoid cell plasticity during human NK cell development","volume":"205","author":"Nalin","year":"2020","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2022.08.005_bib47","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T\u00a0cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.08.005_bib48","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","article-title":"TGFbeta1-Mediated SMAD3 enhances PD-1 expression on antigen-specific T\u00a0cells in cancer","volume":"6","author":"Park","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.08.005_bib49","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ccell.2022.08.005_bib50","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1038\/s41467-019-10335-5","article-title":"Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T\u00a0cell inhibition","volume":"10","author":"Pereira","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.08.005_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aam8825","article-title":"Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells","volume":"359","author":"Ramsuran","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.08.005_bib52","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/s41598-017-02608-0","article-title":"Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma","volume":"7","author":"Ritter","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ccell.2022.08.005_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2022.08.005_bib54","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2022.08.005_bib55","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib56","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2022.08.005_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1084\/jem.190.6.775","article-title":"In\u00a0vivo expression of natural killer cell inhibitory receptors by human melanoma\u2013specific cytolytic T lymphocytes","volume":"190","author":"Speiser","year":"1999","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/febs.13649","article-title":"Serglycin determines secretory granule repertoire and regulates natural killer cell and cytotoxic T lymphocyte cytotoxicity","volume":"283","author":"Sutton","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.ccell.2022.08.005_bib59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.08.005_bib60","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2022.08.005_bib61","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"van Hall","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ccell.2022.08.005_bib62","first-page":"556","article-title":"CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder","volume":"194","author":"Wang","year":"2015","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.ccell.2022.08.005_bib63","article-title":"Myeloid cell-associated resistance to PD-1\/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing","author":"Wang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.08.005_bib64","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T\u00a0cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2022.08.005_bib65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-genom-121119-083418","article-title":"Progress, challenges, and surprises in annotating the human genome","volume":"21","author":"Zerbino","year":"2020","journal-title":"Annu. Rev. Genomics Hum. Genet."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610822003695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610822003695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:06Z","timestamp":1778617386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610822003695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1535610822003695"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2022.08.005","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}